T. Logan - Concepedia

Author

T. Logan

Also Known As

P R Baird-Fraser, T Logan, T. Logan, Ted Logan

Publications

338

Citations

H-Index

Concepts

All Affiliations

T. Logan is an author at The University of Western Australia specializing in oncology, medicine, and cancer therapeutics.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	104
2	Health Sciences	1	1	29
3	Nephrology	1	1	37
4	Neurology	1	1	29
5	Obstetrics	1	1	28

T. Logan

Publications

224

Citations

H-Index

Page 1

	Year	Citations
A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma Ahmad A. Tarhini, Michael Millward, Paul N. Mainwaring, Cancer	2009	120
Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features T. Logan, David F. McDermott, J. P. Dutcher, Journal of Clinical Oncology Surgical OncologyRenal PathologyTemsirolimus EfficacySurgeryLogistic Analysis	2008	37
Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. Donald P. Lawrence, Omid Hamid, David F. McDermott, Journal of Clinical Oncology Neuro-oncologyOncologyPhase Ii TrialHealth SciencesHuman Monoclonal Antibody	2010	29
Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. Gockerman Jp, Spremulli En, M Raney, PubMed Breast OncologyCancer ManagementGynecologyPharmacotherapyEndocrine Oncology	1986	28
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial Jason Chesney, Igor Puzanov, Frances A. Collichio, Annals of Oncology MedicineMelanoma3-Year Landmark AnalysisImmune Checkpoint InhibitorTalimogene Laherparepvec	2019	10

Page 1